Rare disease research: Why EU countries must pool their resources

Written by Yann Le Cam on 6 March 2018 in Opinion
Opinion

Research has increased over the last two decades, but, there is a lack of research to cover every one of over 6000 identified rare diseases, writes Yann Le Cam.

Research has increased over the last two decades, but, there is a lack of research to cover every one of over 6000 identified rare diseases | Photo credit: Adobe Stock


The greatest barrier to the prevention, diagnosis and treatment of rare diseases is insufficient knowledge, including information about the natural history of rare diseases. 

In the past, a lack of rare disease research has delayed the establishment of the fundamental scientific knowledge needed to understand the causes and mechanisms for most rare diseases.

This has resulted in under-diagnosis, misdiagnosis, delays in diagnosis and inappropriate treatment. The key to developing this knowledge is supporting and encouraging all elements of rare disease research.


RELATED CONTENT


Research has increased over the last two decades. However, there is a lack of research to cover every one of over 6000 identified rare diseases.

Research on rare diseases cannot be carried out in isolation. Pooling of scarce resources is essential, not only to avoid duplications but also to optimise the use of funding, infrastructures and technological platforms.

We need to link up infrastructures that perform rare disease research. There is a need for a framework to enable efficient and ethical data sharing on a large scale. 

In addition, there needs to be an organic connection between data coming from healthcare and data from research to achieve a higher degree of integration. The recently established European reference networks (ERNs) can play a pivotal role in enhancing research capabilities.

Through our work, we advocate for more funding for research at European, national and international levels. 

We are involved in specific research projects that structure the research environment, acting as a broker between disease-specific patient organisations and national funders, provide capacity-building trainings for patients so they can be involved and bring the patient voice to research projects and infrastructures.

We need earlier patient access to promising, innovative drugs without compromising patient safety. We need to move from the proof of concept to the first clinical trial more quickly and without compromising patient safety. 

We need more translational research to ensure basic research is translated into medicines for patients. Early access cannot be achieved without the continuous evidence generation.

The rare disease community, including all rare disease patient organisations and their partners, can be deservedly proud of its achievements over the last 20 years. 

We now look to the future with great energy and drive. Building on our collective expertise from experience and shared values, together we will continue to tackle the new challenges that lie ahead.

 

About the author

Yann Le Cam is CEO of EURORDIS-Rare Diseases Europe

Created in 1997, EURORDIS-Rare Diseases Europe is a non-profit alliance of over 700 rare disease patient organisations from more than 60 countries that work together to improve the lives of the 30 million people living with a rare disease in Europe. The vision of EURORDIS is to enable better lives and cures for people living with a rare disease.

Interested in this content?

Sign up to our free daily email bulletins.

 

Share this page

Tags

Categories

Related Partner Content

Childhood Cancer: Benefiting from the best knowledge available in Europe
11 January 2018

The Paediatric Cancer network, ERN PaedCan is helping to break down barriers to effective cross-border healthcare, writes Ruth Ladenstein

PM+: One-time consent on data protection rules a 'necessity' for European health research
13 March 2015

The risk of potentially damaging consequences to Europe's health research if EU policymakers don't get Europe's data protection rules right is clear, argues John Crown.